The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate and Dihydrotestosterone
Abstract
Natural and pharmacological androgen receptor (AR) ligands were tested for their ability to induce the AR NH2-terminal and carboxyl-terminal (N/C) interaction in a two-hybrid protein assay to determine whether N/C complex formation distinguishes in vivo AR agonists from antagonists. High-affinity agonists such as dihydrotestosterone, mibolerone, testosterone, and methyltrienolone at concentrations between 0.1 and 1 nM induce the N/C interaction more than 40-fold. The lower affinity anabolic steroids, oxandrolone and fluoxymesterone, require concentrations of 10-100 nM for up to 23-fold induction of the N/C interaction. However no N/C interaction was detected in the presence of the antagonists, hydroxyflutamide, cyproterone acetate, or RU56187, at concentrations up to 1 microM, or with 1 microM estradiol, progesterone, or medroxyprogesterone acetate; each of these steroids at 1-500 nM inhibited the dihydrotestosterone-induced N/C interaction, with medroxyprogesterone acetate being the most effective. In transient and stable cotransfection assays using the mouse mammary tumor virus reporter vector, all ligands displayed concentration-dependent AR agonist activity that paralleled induction of the N/C interaction, with antagonists and weaker agonists failing to induce the N/C interaction. AR dimerization and DNA binding in mobility shift assays and AR stabilization reflected, but were not dependent on, the N/C interaction. The results indicate that the N/C interaction facilitates agonist potency at low physiological ligand concentrations as detected in transcription, dimerization/DNA binding, and stabilization assays. However the N/C interaction is not required for agonist activity at sufficiently high ligand concentrations, nor does its inhibition imply antagonist activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Kelce, W. R., Monosson, E., Gamcsik, M. P., Laws, S. C., & Gray, L. E. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1117 · Cited by 542
Self-citationEvidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer
Langley, E., Zhou, Z.-X., & Wilson, E. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29983 · Cited by 280
Self-citationLangley, E., Kemppainen, J. A., & Wilson, E. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.92 · Cited by 233
Self-citationYarbrough, W. G., Quarmby, V. E., Simental, J. A., Joseph, D. R., Sar, M., Lubahn, D. B., Olsen, K. L., French, F. S., & Wilson, E. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38972-0 · Cited by 199
Self-citationBirrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1572 · Cited by 87
Cited by
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Chemistry and Structural Biology of Androgen Receptor
Gao, W., Bohl, C. E., & Dalton, J. T. (2005) · Chemical Reviews · doi:10.1021/cr020456u · Cited by 528
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Role of Hormones in Pilosebaceous Unit Development
Deplewski, D., & Rosenfield, R. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.4.0404 · Cited by 443
He, B., Kemppainen, J. A., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 442
Self-citationStanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Jia, L., Moore, N. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 405
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
He, B., Kemppainen, J. A., Voegel, J. J., Gronemeyer, H., & Wilson, E. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37219 · Cited by 372
Self-citationWilson, V. S. (2002) · Toxicological Sciences · doi:10.1093/toxsci/66.1.69 · Cited by 341
Bhasin, S., Calof, O. M., Storer, T. W., Lee, M. L., Mazer, N. A., Jasuja, R., Montori, V. M., Gao, W., & Dalton, J. T. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0120 · Cited by 300
Kraemer, W. J., Ratamess, N. A., Hymer, W. C., Nindl, B. C., & Fragala, M. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00033 · Cited by 300
Turgeon, J. L., Carr, M. C., Maki, P. M., Mendelsohn, M. E., & Wise, P. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0020 · Cited by 264
Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration
Spence, R. D., & Voskuhl, R. R. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.12.001 · Cited by 258
Schaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman, M. S., Ma, A. A. K., Miner, J. N., & Diamond, M. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408819102 · Cited by 208
Liganded Androgen Receptor Interaction with β-Catenin
Pawlowski, J. E., Ertel, J. R., Allen, M. P., Xu, M., Butler, C., Wilson, E. M., & Wierman, M. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200545200 · Cited by 166
Brooke, G. N., Parker, M. G., & Bevan, C. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210955 · Cited by 79
“The wild-type receptor was transcriptionally active not only in the presence of androgens, but also substantially so (>20% maximal activity) in the presence of CPA, oestradiol, MIF, MPA and progesterone, confirming previous studies showing that high concentrations of some of these can activate AR (Berrevoets et al., 1…”
ResultBlake, B. E., & McCoy, K. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.021 · Cited by 21
Metadata
- Authors
- Kemppainen, J. A.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1999-03-01
- Volume
- 13
- Issue
- 3
- Pages
- 440-454
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2043848949
- Cited by
- 207
- References
- 6
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.